indication-specific pricing

Market Access

Leela Barham highlights data that shows that indication-specific pricing has been used in England for at least four years and over 60 times.

News

argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.